Table 1.
Target | BsAbs format (molecule name) | Reference |
---|---|---|
B-cell malignancies | ||
CD19 | BiTE (blinatumomab) | 54, 74, 75 |
CD19 | DART (MGD011, duvortuxizumab) | 47 |
CD19 | Chemically crosslinked | 45 |
CD20 | BiTE | 44 |
CD20 | Chemically crosslinked (CD20bi) | 43, 66-68 |
CD20 | Knobs into hole | 42 |
CD20 | Diabody | 37, 38 |
CD20 | Triomab (FBTA05, lymphomun) | 36, 39, 40, 64 |
CD20 | Heterodimeric (REGN1979) | 41 |
Multiple myeloma | ||
BCMA | BiTE | 51 |
BCMA | Chemically crosslinked | 49 |
BCMA | Knobs into hole/asymmetric (EM801) | 52 |
CD138 | BiTE-Fc | 50 |
Target of Wue-1 | BiTE | 48 |
FcRH5 | Knobs into hole | 11 |
Myeloid malignancies | ||
CD33 | BiTE | 23, 25-28 |
CD33 | Tetravalent tandem diabody | 32 |
CD123 | DART (MGD006) | 30, 31 |
CD123 | BiTE (AMG 330) | 24 |
CD123 | Duobody (JNJ-63709178) | 46 |
CLL1 | Knobs into hole | 33 |
CLL1 | Chemically crosslinked | 29 |
WT1 | BiTE | 21 |
Flt3 | BiTE, Fabsc | 20 |
CD13 | Chemically crosslinked | 22 |
DART, dual-affinity retargeting; Fabsc, fragment antigen binding single chain.